Open Orphan expands volunteer recruitment centres for human challenge trials

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and the world leader in vaccine and antiviral testing using human challenge clinical trials, has opened two new volunteer recruitment centres to screen potential trial volunteers, the first in East London and a second in central Manchester. These new locations are part of the Company’s expansion of its human challenge study trials launching in 2021.

The first new site is a repurposed former coffee shop at the street level of Queen Mary BioEnterprise Innovation Centre (“QMB”), which houses hVIVO’s current 24-bedroom state-of-the-art quarantine clinic in Whitechapel, East London. This is the first time a branded volunteer recruitment centre  has been situated at street level whereby volunteers can walk straight in for screening. The large, multi-use space has the capacity to provide substantially more volunteer medical screening and processing with dedicated private physical exam and consenting rooms, ample hot-desking space and a refreshment area, as well as a dedicated reception area. Importantly, this means the facility can now offer 520 volunteer recruitment visit slots per week, with the intention that this will increase over time. This new centre has processed its first volunteers in recent weeks. Learn more about the screening process at www.flucamp.com/what-is-screening/.

The Company has opened another similar volunteer recruitment facility in central Manchester, broadening its reach and reducing travel time required by potential volunteers to attend the initial visit at our London clinic. It will have an initial capacity for more than 100 visits per week, but this will increase substantially in the weeks that follow. The clinic is due to process its first volunteers on 27 January.

Cathal Friel, Executive Chairman of Open Orphan plc commented: “We are delighted to have had the opportunity to get access to these new volunteer recruitment screening centres and to have them fully operational so quickly. The current pandemic has forced many businesses to close and we are able to provide another use for these spaces not currently in use. These spaces presented an opportunity for us to open street level volunteer recruitment centres quickly and efficiently. The number of volunteers required by hVIVO is increasing rapidly in line with the number of studies the company is running, and these two additional centres will allow us to increase our capacity substantially in the year ahead. Given our extensive pipeline of upcoming contracted studies, we are also continuing to explore additional quarantine facilities.  

We are proud of our hard working and dedicated team for transforming both of these sites in record time into volunteer recruitment screening centres where we can efficiently process more volunteers than ever before.”

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. hVIVO welcomes volunteers to take part in our clinical trials under expertly supervised conditions, to further medical research, and help us to take the understanding of respiratory illnesses to a new level. Volunteers are central to the work that we do; our studies focus on testing new treatments on real people, in a safe, controlled, clinical environment.

Further details on all aspects of our volunteer programs including testimonials from previous volunteers can be found at www.flucamp.com.

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Venn Life Sciences: Medical writing

Team experience Small dedicated team of Senior Medical Writers and Clinical Trial Assistant with total team experience in clinical and regulatory writing of more than 75 years In addition, Venn is working with a flexible shell

Open Orphan Plc

RSV Human Challenge Study
as a tool for a break-through designation

IntroductionAn international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified vaccinia virus Ankara RSV vaccine candidate.

Open Orphan Plc

Open Orphan to commence influenza human challenge study

Candidate exhibits a novel mechanism of action and differs considerably from previously approved drugs Open Orphan – a specialists in testing infectious and respiratory disease products using human challenge clinical trials – has announced that its

Open Orphan Plc

Cocrystal Pharma partners with hVIVO

A growing specialist contract organization, hVIVO—a subsidiary of Open Orphan plc—has been tapped by Cocrystal Pharma to conduct a phase 2a clinical trial of its novel broad-spectrum, orally administered antiviral candidate, CC-42344. Housed in hVIVO’s state-of-the-art

Open Orphan Plc

From bench to clinic: Hurdles in gene therapy development

Gene therapy offers significant potential to treat diseases with high unmet medical need. However, the unique nature of these therapies poses challenges in product development, namely: safety concerns, efficacy issues, or obstacles related to Chemistry, Manufacturing and Controls

Open Orphan Plc

What is FluCamp?

FluCamp is all about improving the health of the population, through increasing understanding around common viral illnesses. Ultimately, the more that we understand about how viruses affect the human immune system, the more quickly we can

Open Orphan Plc

Open Orphan’s hVIVO signs £6.2m human challenge study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has

Open Orphan Plc

Where’s the demand in human challenge clinical trials?

In the early months of the pandemic, human challenge clinical trials drew amplified public interest on its potential to accelerate the hunt for Covid-19 vaccines. Fast forward two years later, while mainstream media buzz around this trial

Open Orphan Plc

The lowdown on hay fever

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can also be to dust, mould or

Open Orphan Plc

How to stay healthy in your 20’s

In your 20’s life tends to change dramatically – and it can be easy to let your health take a back seat. However, it is a period in which is vital to establish a healthy lifestyle,

Open Orphan Plc

CMC team capabilities New Chemical Entities

For 20+ years, members of the CMC (Chemistry Manufacturing and Control) team have supported and are supporting numerous pharmaceutical companies to ensure the timely development and manufacture of high-quality drug substances and drug products for non-clinical-

Open Orphan Plc

Omicron: The Lowdown

The COVID pandemic started at the turn of 2020. The virus was first detected in Wuhan, China and since then has spread around the globe and mutated into several different strains. As of June 2022, the

Open Orphan Plc

The best supplements to support your health

The winter season can wreak havoc on your immune system, particularly when we spend much of our time huddled indoors, and our diet may become a little more carbohydrate based. Fortunately, science has allowed us to

Open Orphan Plc

Research backs the annual flu jab

The flu jab has encountered some controversy during its time in circulation. However, recent research suggests that some of these rumoured negative effects may in fact not be true – and actually, the opposite might apply.

Open Orphan Plc

CMC team capabilities for biologics

For 20+ years, members of the CMC (Chemistry, Manufacturing and Controls) team supported numerous (bio)pharmaceutical and biotechnological companies to ensure the development and manufacture of high-quality drug substances and drug products for » CMC management and